Moderna Pays Up to $2.25 Billion to End COVID Vaccine Patent War
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.
Arbutus Biopharma shares dropped 16% after losing European patent dispute with Moderna. The biotech plans to appeal the ruling that affects ongoing litigation.